Literature DB >> 8093499

Creutzfeldt-Jakob disease and blood transfusion.

T F Esmonde1, R G Will, J M Slattery, R Knight, R Harries-Jones, R de Silva, W B Matthews.   

Abstract

Epidemiological surveillance of Creutzfeldt-Jakob disease (CJD) in the UK identified 21 patients who had received a blood transfusion and 29 who had donated blood, out of a total of 202 definite and probable cases. This frequency of blood transfusion or donation did not differ from that in age and sex matched controls, and the clinical features in patients with a history of blood transfusion were similar to those of classical CJD and clearly distinct from CJD in recipients of human growth hormone. This evidence does not suggest that blood transfusion is a major risk factor for CJD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093499     DOI: 10.1016/0140-6736(93)90068-r

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies.

Authors:  K Wilson; C Code; M N Ricketts
Journal:  BMJ       Date:  2000-07-01

2.  Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.

Authors:  Niels S Vermeer; Sabine M J M Straus; Aukje K Mantel-Teeuwisse; Francois Domergue; Toine C G Egberts; Hubert G M Leufkens; Marie L De Bruin
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

Review 3.  Is Creutzfeldt-Jakob disease transmitted in blood? Is the absence of evidence of risk evidence of the absence of risk?

Authors:  M N Ricketts
Journal:  CMAJ       Date:  1997-11-15       Impact factor: 8.262

Review 4.  Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: integrating science, legal duties and ethical mandates.

Authors:  T Caulfield; J Dossetor; L Boshkov; J Hannon; D Sawyer; G Robertson
Journal:  CMAJ       Date:  1997-11-15       Impact factor: 8.262

Review 5.  Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: implications for physicians.

Authors:  C MacKnight; K Rockwood
Journal:  CMAJ       Date:  1996-09-01       Impact factor: 8.262

6.  Emerging problems in prion disease.

Authors:  V Dodelet; M Ricketts; N R Cashman
Journal:  CMAJ       Date:  1996-09-01       Impact factor: 8.262

Review 7.  Is Creutzfeldt-Jakob disease transmitted in blood?

Authors:  M N Ricketts; N R Cashman; E E Stratton; S ElSaadany
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

8.  Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: theoretical risk for real people.

Authors:  S M King; H Watson; H Heurter; M Ricketts; S Elsaadany
Journal:  CMAJ       Date:  1998-10-06       Impact factor: 8.262

9.  Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission.

Authors:  Caroline Lacroux; Daisy Bougard; Claire Litaise; Hugh Simmons; Fabien Corbiere; Dominique Dernis; René Tardivel; Nathalie Morel; Stephanie Simon; Séverine Lugan; Pierrette Costes; Jean Louis Weisbecker; François Schelcher; Jacques Grassi; Joliette Coste; Olivier Andréoletti
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

10.  A case-control study of sporadic Creutzfeldt-Jakob disease in Switzerland: analysis of potential risk factors with regard to an increased CJD incidence in the years 2001-2004.

Authors:  Jessica Ruegger; Katharina Stoeck; Lorenz Amsler; Thomas Blaettler; Marcel Zwahlen; Adriano Aguzzi; Markus Glatzel; Klaus Hess; Tobias Eckert
Journal:  BMC Public Health       Date:  2009-01-14       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.